Rong Liu1, Tian Wang1, Bao Zhang1, Li Qin2, Changrui Wu2, Qingshan Li1, Le Ma1. 1. School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China. 2. The First Affiliated Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, China.
Abstract
PURPOSE: To evaluate the effects of lutein and zeaxanthin on visual function in randomized controlled trials (RCTs) of AMD patients. METHODS: Relevant studies were identified by searches on PubMed, EMBASE, Web of Science, and Cochrane Library database up to April 2014. Three investigators independently determined the eligibility of RCTs, which compared lutein and zeaxanthin intervention with placebo. The adjusted weighted mean differences (WMDs) from each study were extracted to calculate a pooled estimate with its corresponding 95% confidence interval (CI). The main outcome measurements included visual acuity (VA), contrast sensitivity (CS), glare recovery time (GRT), and subjective perception of visual quality. RESULTS: Eight RCTs involving 1176 AMD patients were included in the meta-analysis. Xanthophyll carotenoids supplementation was associated with significant decrease in logMAR levels compared with the placebo group (WMD, -0.04; 95% CI, -0.06 to -0.03), and during intervention, each 1-mg/day increase in these carotenoids supplementation was related to a 0.003 reduction in logMAR level of VA. Remarkable benefit was also observed at all four spatial frequencies of CS (WMD ranging from 0.08-0.18; all P < 0.05) in contrast to placebo. Furthermore, association was observed between the postintervention increase in macular pigment optical density and improvements in VA (r = -0.58; P = 0.02), and in CS at 12 cycles/degree as well (r = 0.94; P < 0.001). CONCLUSIONS: Lutein and zeaxanthin supplementation is a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To evaluate the effects of lutein and zeaxanthin on visual function in randomized controlled trials (RCTs) of AMDpatients. METHODS: Relevant studies were identified by searches on PubMed, EMBASE, Web of Science, and Cochrane Library database up to April 2014. Three investigators independently determined the eligibility of RCTs, which compared lutein and zeaxanthin intervention with placebo. The adjusted weighted mean differences (WMDs) from each study were extracted to calculate a pooled estimate with its corresponding 95% confidence interval (CI). The main outcome measurements included visual acuity (VA), contrast sensitivity (CS), glare recovery time (GRT), and subjective perception of visual quality. RESULTS: Eight RCTs involving 1176 AMDpatients were included in the meta-analysis. Xanthophyll carotenoids supplementation was associated with significant decrease in logMAR levels compared with the placebo group (WMD, -0.04; 95% CI, -0.06 to -0.03), and during intervention, each 1-mg/day increase in these carotenoids supplementation was related to a 0.003 reduction in logMAR level of VA. Remarkable benefit was also observed at all four spatial frequencies of CS (WMD ranging from 0.08-0.18; all P < 0.05) in contrast to placebo. Furthermore, association was observed between the postintervention increase in macular pigment optical density and improvements in VA (r = -0.58; P = 0.02), and in CS at 12 cycles/degree as well (r = 0.94; P < 0.001). CONCLUSIONS: Lutein and zeaxanthin supplementation is a safe strategy for improving visual performance of AMDpatients, which mainly showed in a dose-response relationship. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Sebastian Mueller; Carlo Krupp; Sven Schnichels; Johanna Hofmann; Martin Spitzer; Karl Ulrich Bartz-Schmidt; Peter Szurman; Kai Januschowski Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-02-20 Impact factor: 3.117
Authors: Dumitrita Iftime; Andreas Kulik; Thomas Härtner; Sabrina Rohrer; Timo Horst Johannes Niedermeyer; Evi Stegmann; Tilmann Weber; Wolfgang Wohlleben Journal: J Ind Microbiol Biotechnol Date: 2015-10-03 Impact factor: 3.346
Authors: David Kelly; Robert F Coen; Kwadwo Owusu Akuffo; Stephen Beatty; Jessica Dennison; Rachel Moran; Jim Stack; Alan N Howard; Riona Mulcahy; John M Nolan Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472